

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

MYLAN PHARMACEUTICALS INC.,
Petitioner,

v.

ASTRAZENECA
Patent Owner.

Patent No. RE44,186

DECLARATION OF DAVID P. ROTELLA, PH.D.

TABLE OF CONTENTS

I.	QUALIFICATIONS.....	1
II.	SCOPE OF WORK	2
III.	OVERVIEW OF THE '186 PATENT.....	3
IV.	FILE HISTORY OF THE '186 PATENT	6
V.	LEGAL STANDARDS	10
VI.	LEVEL OF ORDINARY SKILL AND RELEVANT TIME	12
VII.	CLAIM CONSTRUCTION	17
VIII.	THE STATE OF THE PRIOR ART.....	17
IX.	PRIOR ART REFERENCES DISCLOSE OR SUGGEST EACH OF THE CLAIMED FEATURES OF THE '186 PATENT.....	26
X.	CONCLUDING STATEMENTS	98
XI.	APPENDIX – LIST OF EXHIBITS	100

I, David P. Rotella, declare as follows:

I. QUALIFICATIONS

1. My name is David P. Rotella. I am currently the Margaret and Herman Sokol Professor of Chemistry in the Department of Chemistry and Biochemistry and in the Sokol Institute of Pharmaceutical Life Sciences at Montclair State University. I have been a member of the faculty of this university since 2011.

2. I am currently an adjunct professor in the Department of Pharmaceutical Sciences at the University of Pittsburgh, in the Center for Drug Discovery at Northeastern University, and in the Department of Medicinal Chemistry at the University of Mississippi. I have been a member of the faculty of these departments since 2010, 2010, and 2009, respectively.

3. I am currently a registered pharmacist in the Commonwealth of Pennsylvania.

4. I was formerly a research scientist at multiple pharmaceutical companies during the years 1991-2010, including at Bristol-Myers Squibb PRI, Lexicon Pharmaceuticals, and Wyeth Research/Pfizer. My industry experience focused on drug discovery and development.

5. I received my B.S. Pharm. from the University of Pittsburgh in 1981 and Ph.D. in Medicinal Chemistry from The Ohio State University in 1985. I was a Postdoctoral Scholar in the Department of Chemistry at The Pennsylvania State University from 1985 to 1987.

6. My current research focuses on protein kinase inhibitors for anti-infective and anti-inflammatory applications. Specifically, I work on the discovery of new agents useful for the potential treatment of parasitic and neurodegenerative diseases, including the synthesizing of new analogs of a lead structure as potential protein kinase inhibitors and investigation of structure-activity relationships in a product that has HSP90 inhibitor activity.

7. I have authored or co-authored more than 20 abstracts for presentation at professional meetings, 40 peer-reviewed journal articles, and seven book chapters. I have also edited or co-edited five books in the field of Medicinal Chemistry. I have received numerous honors, fellowships and awards, and am an inventor or co-inventor on seven granted patents.

8. A summary of my education, experience, publications, awards and honors, patents, publications, and presentations is provided in my CV, a copy of which is submitted separately (Ex. 1004).

II. SCOPE OF WORK

9. I understand that a petition is being filed with the United States Patent and Trademark Office for *Inter Partes* Review of U.S. Reissued Patent No. RE44,186 (hereinafter, “the ’186 patent,” Ex. 1001). I have been retained by Mylan Pharmaceuticals Inc. as a technical expert to provide opinions regarding the ’186 patent. I have reviewed the ’186 patent and relevant sections of its prosecution history in the US Patent and Trademark Office (Ex. 1006). I have also reviewed and considered other documents in arriving at my opinions, and cite them in this declaration. For convenience, documents cited in this declaration are listed

in the Appendix in Section XI.

10. I am compensated at the rate of \$500/hour for my work. I have no financial interest in the outcome of this matter.

III. OVERVIEW OF THE '186 PATENT

11. The '186 patent is entitled "Cyclopropyl-Fused Pyrrolidine-Based Inhibitors of Dipeptidyl Peptidase IV and Method" and was issued on April 30, 2013. I have been advised that the '186 patent issued from U.S. Application No. 13/308,658, which was filed on December 1, 2011, as a reissued application of U.S. Application No. 09/788,173, which was filed on February 16, 2001 and issued as U.S. Patent No. 6,395,767 on May 28, 2002. I have also been advised that U.S. Application No. 09/788,173 claims priority to U.S. Provisional Application No. 60/188,555, which was filed on March 10, 2000.

12. The '186 patent is generally directed to cyclopropyl-fused pyrrolidine-based compounds with a variety of optional substituents, as well as pharmaceutical combinations and methods for treating diabetes and additional diseases. According to the '186 patent, the "cyclopropyl-fused pyrrolidine-based compounds [of the '186 patent are] inhibitors of dipeptidyl peptidase IV [(DP-IV)] . . . for treating diabetes, especially Type II diabetes." Ex. 1001 col. 1, ll. 19-21. The '186 patent describes the mechanism by which DP-IV inhibition treats type 2 diabetes as follows: "[DP-IV] has been shown to be the primary degrading enzyme of GLP-1(7-36) in vivo . . . [t]hus, inhibition of [DP-IV] in vivo should potentiate endogenous levels of GLP-1(7-36) and . . . thus serve to ameliorate the diabetic condition." *Id.* at Col. 1, ll. 59-67.

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.